Press Releases Kaken Pharmaceutical Co., Ltd.

Equities

4521

JP3207000005

Delayed Japan Exchange Other stock markets 01:11:21 13/05/2024 BST			5-day change	1st Jan Change
3,510 ^JPY	-0.28%		+1.30%	+4.71%

2023	Kaken Pharmaceutical Co., Ltd. Declares Dividend for the Second Quarter of Fiscal Ending March 2024, Payable on November 30, 2023; Provides Dividend Guidance for the Full Year Ending March 31, 2024	CI
2023	Kaken Pharmaceutical Co., Ltd. Provides Consolidated Financial Forecast for Fiscal Year Ending March 31, 2024	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Kaken Pharmaceutical : Presentation material for meeting	11-08	PU
Kaken Pharmaceutical : Reference Data of Financial Statements for the 2Q of Fiscal 2023	11-07	PU
Kaken Pharmaceutical : Corporate Report 2023	11-01	PU
Kaken Pharmaceutical : Reference Data of Consolidated Financial Results for 1st Quarter of Fiscal 2023	04/08/23	PU
MediWound Announces Commercial Launch of NexoBrid in Japan	02/08/23	AQ
Numab Therapeutics Announces First Subject Dosed in Phase 1 Clinical Study of NM26 Program	16/05/23	AQ
Kaken Pharmaceutical : Presentation material for meeting	11/05/23	PU
Kaken Pharmaceutical : Reference Data of Financial Statements Fiscal 2022	10/05/23	PU
Kaken Pharmaceutical : Consolidated Financial Results for the Fiscal 2022	09/05/23	PU
Kaken Pharmaceutical : Reference Data of Financial Statements for the 3Q of Fiscal 2022	03/02/23	PU
Kaken Pharmaceutical : Consolidated Financial Results for the Third Quarter of Fiscal 2022	02/02/23	PU
Kaken Pharmaceutical : November 10, 2022 We have posted Corporate Report 2022.	10/11/22	PU
Kaken Pharmaceutical : Presentation material for meeting	09/11/22	PU
Kaken Pharmaceutical : Consolidated Financial Results for the Second Quarter of Fiscal 2022	07/11/22	PU
Kaken Pharmaceutical : Consolidated Financial Results for the First Quarter of Fiscal 2022	02/08/22	PU
Kaken Pharmaceutical : Reference Data of Financial Statements for the 1Q of Fiscal 2022	02/08/22	PU
Kaken Pharmaceutical : Submission of Marketing Authorization Application for efinaconazole in Europe	01/06/22	PU
Kaken Pharmaceutical : Announcement on Recording of Extraordinary Losses and Revisions to the Full-year Earnings Forecast	29/03/22	PU
Kaken Pharmaceutical : ［Delayed］［Summary］Consolidated Financial Results for the Third Quarter of Fiscal 2021	15/02/22	PU
Kaken Pharmaceutical : Completes Acquisition of ARTham Therapeutics Inc.	13/12/21	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Kaken Pharmaceutical Co., Ltd.

Equities

4521

JP3207000005

Press Releases

Filters